“If it eventually moves into human trials and proves that it works in humans and it’s well tolerated, it’s a game-changer. It’s a game-changer for heart attacks.”
The U.S. Patent and Trademark Office recently announced they will grant a patent to the MDI Biological Laboratory. The patent will allow the lab to use a molecule named MSI-1436, which could be used to stimulate the regeneration and repair of heart tissue.
“Heart disease is the leading cause of death in the entire western world. In fact, it kills more people than AIDS and all the different types of cancers combined. What this study shows is tremendous promise for those who have heart disease.”
“It will, hopefully as it does in animal models, stimulate repair and regeneration of the damaged heart muscle.”
Scientists caution that MSI-1436 is not yet ready for humans, and it won’t be for some time. However, the lab has been researching the drug on zebrafish and mice. So far, the results have been positive.
“The adult zebrafish and the adult mouse have been separated by hundreds of millions of years of evolution. So the fact that this drug works in both of these animal systems would suggest that we really hit a critical target that’s important for this process.”
The drug has other potential benefits as well, including for the treatment of muscular dystrophy. The president of the lab also believes its development could impact the area.
“I think helping to do this in a state like Maine would stimulate more activity like this and help to modernize and grow the economy in a way that that makes sense for where we are today.”
As of right now, there is still a lot of research left to do. But scientist believe that the new patent will be a big step forward.
“We have a good start out of the gate. It is a long road but I think if MSI-1436 works as we would predict in humans, then we would have something incredibly impactful for human health.”
Heart Disease, Muscular Dystrophy, Organ Regeneration, Regenerative Biology